anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is an intervention study in which participants will be randomized as to the order in which each of the two sessions are completed. Forty post-ACLR will who present with between-limb gait differences will perform two asymmetric walking sessions where they will walk with between-limb gait speed differences of 0.25 m/s and 0.50 m/s at three 15-minute intervals to evaluate the restoration of healthy gait. Post-ACLR participants will perform an asymmetric walking intervention protocol session on two different days. On one day they will perform the protocol with a 0.25 m/s between-limb difference and on a separate day they will perform the protocol with a 0.50 m/s between limb difference. For the 0.25 m/s condition, one limb will be set to 1.0 m/s and the other 1.25 m/s (i.e., 1.0 m/s - 1.25 m/s). Similarly, for the 0.50 m/s condition, one limb will be set to 1.0 m/s and the other 1.50 m/s (i.e., 1.0 m/s - 1.50 m/s). Each participant will perform both the 0.25 m/s and 0.50 m/s protocols on separate days, and we will randomize who performs which protocol first or second. At least 3 weeks must pass between the two one-day sessions. Patient-specific simulations will be generated in OpenSim for each of the 40 post-ACLR individuals to assess differences in knee joint loading. Together with machine learning, these models will help evaluate the effectiveness of the asymmetric walking protocol in reducing detrimental knee loading. The study team hypothesizes that the 0.50 m/s perturbation will produce a larger reduction in between-limb asymmetry than the 0.25 m/s perturbation and reduce detrimental knee loading.
PURPOSE:Propylene glcyol oleic acid ester of low toxicity and scarce irritation is used as a solublizer to give the title composition which contains riboflavin butyrate as much as a few percents in a stably dissolved form even at low temperature. CONSTITUTION:Oleic acid propylene glycol ester is used as a solubilizer for riboflavin butyrate to give the title composition containing less than 5wt% of riboflavin butyrate. The oleic acid propylene glycol ester has very little irritation, differing from fatty acid glycerol ester or fatty acid sorbitol ester. The composition develops no turbid or precipitation to keep clarity for a long period of time at low temperature. The composition containing riboflavin burate may be mixed with other ingredients such as liposoluble vitamins and food oil. The amount of the propylene glycol oleic ester is preferably 20-75wt% based on the composition.
Patients will receive education and re-assurance in the same manner as the usual care group and will receive physical therapy during the initial 4 weeks following enrollment. Physical therapy will be based on evidence and prior research evaluating a centralizing treatment program for patients with LBP and sciatica. The first physical therapy session will be scheduled within 3 days after enrollment and 6-8 sessions will be administered in the first 4 weeks. Each session will include a brief assessment, treatment with centralizing exercises and spinal mobilizations. Mechanical traction is an optional component. Patients will be provided handouts and instructed to perform assigned exercises at home every 4-5 hours on days between sessions.
Patients receive irinotecan hydrochloride as in Arm A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Glioma is the most common type of primary intracranial malignant tumor, and because of its high invasiveness and recurrence, its prognosis remains poor. The present study investigated the biological function of piggyBac transportable element derived 5 (PGBD5) in glioma. Glioma and para-cancerous tissues were obtained from five patients. Reverse transcription-quantitative PCR and western blotting were used to detect the expression levels of PGBD5. Transwell assay and flow cytometry were used to evaluate cell migration, invasion, apoptosis and cell cycle distribution. In addition, a nude mouse tumor transplantation model was established to study the downstream pathways of PGBD5 and the molecular mechanism was analyzed using transcriptome sequencing. The mRNA and protein expression levels of PGBD5 were increased in glioma tissues and cells. Notably, knockdown of PGBD5 in vitro could inhibit the migration and invasion of glioma cells. In addition, the knockdown of PGBD5 expression promoted apoptosis and caused cell cycle arrest in the G2/M phase, thus inhibiting cell proliferation. Furthermore, in vivo experiments revealed that knockdown of PGBD5 expression could inhibit Ki67 expression and slow tumor growth. Changes in PGBD5 expression were also shown to be closely related to the peroxisome proliferator-activated receptor (PPAR) signaling pathway. In conclusion, interference with PGBD5 could inhibit the malignant progression of glioma through the PPAR pathway, suggesting that PGBD5 may be a potential molecular target of glioma.
Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity. Read circulars for lithium preparations before use of such concomitant therapy.

EDECRIN may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. Their concurrent use should be avoided.

A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs.

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when EDECRIN and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
The invention discloses a Lepista sordida strain and a method for cultivating sporocarp by using liquid strain thereof. The invention provides Lepista sordida (Lepista sordida) DCH618, the preservation number of which is CGMCC No. 1699. Experiments prove that the fruiting body rich in nucleoside compounds and/or ergosterol can be obtained by cultivating Lepista sordida (Lepista sordida) DCH618 liquid seed, and large-scale industrial cultivation can also be realized. Therefore, Lepista sordida (Lepista sordida) DCH618 has important application value in food processing, medicine processing or health care product processing. The invention has important application value.
Provided is a pharmaceutical composition which is effective as an anti-cancer immunostimulating therapy. Said pharmaceutical composition has a compound set forth in general formula (I) or a salt thereof as an active ingredient {in the formula, one of X1 and X2 is a hydroxy group, a morpholino alkylcarbonyloxy group, an alkylcarbonyloxy group, a phosphate group, an alkoxy group, a di(alkyl)amino alkyl triazolyl group, an acetoxy group in which at least one hydrogen atom may be halogenated, an azide group, or a sulfate group, and the other is a hydrogen atom. Alternatively, X1 and X2 together represent an oxo group. Y represents a C1-6 alkyl group or a hydrogen atom. Z1 and Z2 are different and represent a group represented by formula (II), a hydroxy group, an ethynyl group, an alkylcarbonyloxy group, a hydrogen atom, or a heterocyclic ring group which may have a substituent. Alternatively, Z1 and Z2 together represent an oxo group. The double line formed from a solid line and a dotted line means a single bond or a double bond. The symbols in formula (II) are as follows: R1 is an alkyl group or a hydrogen atom; R2 is a hydroxy group, an alkyl group, an alkoxy group, a group represented by formula (III) [in formula (III), * means a bond with a carbon atom of the carbonyl group in formula (II)], or -N(R3)(R4) (R3 and R4 are the same or different, and are a hydrogen atom, an alkyl group, a phenyl alkyl group, or a group represented by formula (IV) (in formula (IV), p is an integer from 1-10 and * means a bond with a carbon atom of the carbonyl group in formula (II)). Alternatively, R3 and R4 together form a heterocyclic ring together with a nitrogen atom); n is an integer which is 0, 1, or 2; and m is an integer which is 1 or 0}.
Chimeric viruses having a vesicular stomatitis virus (VSV) background where the VSV G protein is supplemented or replaced with an alphavirus glycoprotein(s), or a functional fragment(s) thereof, are provided. A preferred alphavirus is Chikungunya virus. In particular embodiments, the glycoprotein(s) is or includes E3, E2, K6, and E1 proteins of an alphavirus, preferably Chikungunya virus. Methods of using the chimeric viruses for treatment of cancers, particularly brain cancers and metastasis thereof are also provided. In some embodiments, the chimeric viruses retain superior oncolytic activity to infect and destroy cancer cells selectively, such as glioblastoma and intracranial melanoma metastases. In some embodiments, the chimeric viruses have reduced toxicity to e.g., heathy cells relative to a control such as the parent VSV with the VSV G protein.
Run-in Phase: All participants will receive oral deuterated water (D2O) for 3 weeks prior to the Treatment Phase of the study. The participants will consume 50mL 70% D2O three times per day (TID) for 7 days, followed by a 50ml 70% D2O dose twice daily (BID) for the next 2 weeks. Treatment Phase: Subjects will receive testosterone matching placebo IM injection one per week and 50 mL 70% D2O dose BID for 3 weeks.
PURPOSE:To obtain the subject composition having an improved activity by carrying out roasting and subsequently enzymatically treating vegetable seeds, etc., adding a vegetable oil thereto, washing the resultant composition by a nonpolar solvent and then extracting the residual insoluble matter by a polar solvent. CONSTITUTION:Vegetable seeds or embryo buds are roasted and subsequently treated with an enzyme in order to liberate a large amount of low molecular antiactive oxygen substances. A vegetable oil is added thereto to prepare a composition having an antiactive oxygen effect. The resultant composition is washed using a nonpolar solvent (benzene, n-hexane, ether, etc., are suitable) for removal of pigments and liposoluble substances and the residual insoluble matter is then extracted using a polar solvent (acetone or lower alcohol is suitable). The obtained extract is concentrated and evaporated to dryness, thus obtaining the objective composition concentrated to (1/10) or lower weight of that of the raw material composition. The above-mentioned composition has an inhibitory effect on active oxygen, a radical scavenging action found by the DPPH method, a lipoperoxide production-inhibitory effect, a prevention effect on rat ventricular irregular pulse and an antiinflammatory effect.
Ridaforolimus is given as an IV infusion over 30 minutes on days 1-5 and 15-19 of each 28 day cycle. For children less than 10 kg body weight, dosing will be adjusted.
BACKGROUND: In 2020, the International Lung Cancer Study Group (IASLC) Pathology Committee established a grading system for non-mucinous primary lung adenocarcinomas. This grading system is based on whether areas of high-grade patterns are present in more than 20% of the tumor. Parameters, such as necrosis, mitotic activity, lymphovascular invasion (LVI) and spread through air spaces (STAS), are excluded from evaluating the grading system.
METHODS: A total of 217 patients' lung resection materials for primary lung adenocarcinoma were re-reviewed using the IASLC grading system. Necrosis, mitotic activity, LVI status and STAS were also evaluated in the resection materials, aiming to demonstrate the relationship between these histopathological features and clinical outcome data.
RESULTS: At all stages, overall survival (OS) and recurrence-free survival (RFS) were related to grade (p=0.011 and 0.024, respectively). Additionally, patients with necrosis were associated with worse OS and RFS (p=0.002 and 0.048, respectively). When grade 2 and 3 tumors were analyzed individually, a significant relationship was found between necrosis and OS in grade 3 tumors (p=0.002). Patients with a high mitotic count (≥10/10 high-power fields) had significantly worse OS (p=0.046). The prevalence of LVI and STAS increased with grade; however, their prognostic significance has not been demonstrated.
CONCLUSIONS: The new grading system provides a highly efficient prognostic classification for survival. Necrosis and high mitotic count are important prognostic parameters for survival. Additionally, necrosis is a stage-independent prognostic factor for OS in grade 3 tumors, although no effect on prognosis can be demonstrated in grade 2 tumors.
Patients undergo radiation therapy on days 1 and 2 tumor-bearing lymph node, and receive CAS3/SS3 intratumorally on days 2, 4, 16, and 18. Patients assigned to dose level 3 also receive CAS3/SS3 intratumorally on days 9, 11, 23, and 25.
A non-synthetic biodegradable starch-based composition is described comprising starch, plasticizer, reinforcing filler, binder, in the presence or absence of alkali or salt, and water. The starch-based composition is subjected to transformation process to produce various foam-liked products, having closed cell structure with dense skin layer. These products are particularly suitable for use as disposal or single-used food packages or containers. These products are to substitute the shape bodies currently used made of plastic or plastic foam. A transformation process of the non-synthetic biodegradable starch-based composition into various foam-liked products is also described. The process is either injecting or compressing the starch-based composition and forming a desired shape in a closed mould at a temperature ranging from 150 to 300 degree Celcius until the gelatinization of starch has been accomplished.
OBJECTIVES: I. Evaluate the response rate of patients with stage IIIB or IV nonsmall cell lung cancer to different schedules of docetaxel and gemcitabine therapy. II. Evaluate the toxicity of this treatment in these patients. III. Describe the quality of life parameters of patients receiving this combination therapy. IV. Determine the survival rate of these patients.

OUTLINE: This is a randomized study. Patients are stratified by disease (stage IIIB vs stage IV) and performance status (0 vs 1). Patients are randomized to one of two treatment arms (Arm I now closed). Arm I: Patients receive docetaxel IV over 1 hour on day 1 followed by gemcitabine IV over 30 minutes on days 1, 8, and 15. (closed as of 8/31/1999) Arm II: Patients receive docetaxel IV over 1 hour and gemcitabine IV over 30 minutes on days 1 and 15. Arm III: Patients receive docetaxel IV on day 1 and gemcitabine IV on days 1, 8, and 15. Patients continue treatment every 28 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with either stable disease or complete/partial response who discontinue treatment after 4-6 courses may be eligible for NCCTG-97-24-51. Quality of life is assessed before treatment and before each course of therapy. Patients are followed every 3 months for 1 year, then every 3 months for 5 years.

PROJECTED ACCRUAL: A total of 19-53 patients will be accrued for this study within 6-18 months.
The invention provides a traditional Chinese medicine composition for treating neurasthenia. The raw materials of the traditional Chinese medicine composition are composed of xylitol, ginseng, semen cuscutae, epimedium, morinda officinalis, cistanche, eucommia bark, honeysuckle, semen cassiae, wallich and talcum powder. The traditional Chinese medicine composition has a certain therapeutic effect in treating hypertension, myocardial dystrophy, coronary sclerosis, angina pectoris and the like and can alleviate various symptoms. By the traditional Chinese medicine composition, the stomachache of patients suffering from the chronic gastritis disappears, and the appetite thereof is enhanced. Meanwhile, the stools of patients suffering from the chronic gastritis are normal and the total acidity of the gastric juice thereof is increased. For asthenic type psychiatric patients, asthenic and depressive type psychiatric patients, schizophrenia patients, psychiatric patients caused by poisoning and infectious diseases, degenerative type psychiatric patients and the like, the above traditional Chinese medicine composition has therapeutic effects. The traditional Chinese medicine composition has a significant excitatory effect on the nervous system. The traditional Chinese medicine composition improves the action performances of a human body, reduces the fatigue, eliminates or relieves the symptoms of general weakness, headache, insomnia and the like, and nourishes the vigour.
In the CG patients, who constitute the Comparison Group, the same non-drug fluid support therapy applied in device therapy will be repeated (isotonic, isolated 500 ml). As both groups of patients will receive fluid support therapy, the impact of the device on the disease will be observed with monitored parameters.
Low back pain (LBP) is an extremely common symptom experienced by people of all ages. The current incidence, prevalence and disability-adjusted life years (DALYs) account for 245.9 million cases/year (15th worldwide cause; 32.4% cases associated with leg pain), 577.0 million cases (15th worldwide cause) and 64.9 million DALYs (6th worldwide cause), respectively. In recent decades, the biopsychosocial model has been applied as a framework for understanding the complexity of low back pain disability in preference to a purely biomedical approach. Considering the large population of patients with LBP and limited medical resources, the development of brief and efficient prognostic clinical tools for use in routine practice is particularly significant. Recent data from epidemiological studies suggest that LBP could affect the physical function of young and older individuals differently. The age-related differ¬ences in the prevalence of some low back pathologies may explain the differential treatment outcomes. The aim of the study is to explore the age bias on biopsychosocial factors in persons with non-specific low back pain.
A stable medicinal cannabidiol composition for use in oral delivery, the composition comprising synthetic cannabidiol (CBD) having a purity of at least 99.5 %, preferably at least 99.8 %, together with beta-caryophyllene (BCP) which functions as both a solvent and antioxidant in the present compositions. The compositions further contain at least one additional lipophilic solvent (e.g. medium chain triglycerides (MCT) and coconut oil) and at least one additional antioxidant (e.g. alpha tocopherol (vitamin E)). The composition is substantially free of other cannabinoids, terpenes, solvents, and pharmaceutically active ingredients. Also disclosed are methods of making and stabilizing CBD in an oral composition.
INTRODUCTION: Irritable bowel syndrome (IBS) is associated with a high prevalence of anxiety and depression. This study aimed to evaluate the effects of a traditional Persian herbal formula containing Melissa officinalis, Pimpinella anisum, and Rosa damascena (MPR) on anxiety and depression in IBS patients with symptoms of constipation-predominant IBS (IBS-C).
METHODS: This double-blind randomized clinical trial was conducted in Afzalipour Hospital via block randomization method. A total of 96 IBS-C patients (based on Rome IV criteria), aged 18-60 years, were included in this study. Participants received capsules containing either 500 mg of herbal formula or placebo (cornstarch) twice a day for four weeks Anxiety and depression were assessed using the Hospital Anxiety and Depression Scale.
RESULTS: Forty-three patients in the intervention group and 45 patients in the control group completed this study. Except for the education level, there were no significant differences in the demographic characteristics between the two groups (P > 0.05). The mean levels of anxiety and depression, and total IBS symptom severity score showed no significant differences between the two groups at baseline (P > 0.05). After four weeks of treatment, the anxiety score considerably improvement in the treatment group (Cohen's d = -1.19, 95 % confidence intervals [CIs] -4.49 to 2.13), as did the depression score (Cohen's d = -1.93, 95 % CIs -4.32 to 2.79).
CONCLUSION: MPR considerably improved anxiety and depression in patients with IBS-C compared to the placebo without serious side effects.
The intervention group will receive SBRT treatment. The specific plan for SBRT is to target the primary tumor region with 24Gy/3. After the completion of SBRT, patients will continue the remaining courses of neoadjuvant chemotherapy.
A gonadotropic hormone preparation is obtained from the blood plasma or serum of pregnant mares by first precipitating the proteins, without previous drying of the material, by addition of known protein precipitating agents, e.g. picric acid, trichloroacetic acid and sulphosalicylic acid, concentrating the liquid and precipitating the hormone therefrom.  The concentration must be effected at reduced pressure and the concentrate is preferably subjected to dialysis, the hormone being non-diffusible through a semi-permeable membrane.  The concentrate is preferably precipitated in two stages, first by the addition of a salt such as solid ammonium sulphate followed by redissolving the precipitate in water and a further dialysis to remove the precipitant, the solution being then precipitated by an organic water soluble substance, e.g. methyl or ethyl alcohol or acetone with the addition of a proportion of an electrolyte such as sodium chloride to increase the proportion of hormone precipitated. The hormone so precipitated is stated to be free from substances which give protein reactions.
The present invention relates to a nasal cavity preparation containing scutellaria root extracts and an application of the nasal cavity preparation. Scutellaria root extracts used as active ingredients are combined with medicinal auxiliary materials by optional proportion to prepare various preparations directly used in nasal cavities, such as nasal cavity drop agents, gelling agents, powder spraying agents, spraying agents, aerosols, micro globules, etc. 30 to 100% of total flavonoid is contained in the scutellaria root extracts, wherein monomeric compounds of baicalin, or wogonoside, or baicalin salt, or wogonoside salt, or scutellarin, or wogonin account for 30 to 100% of the total flavonoid. The nasal cavity preparation for treating rhinitis and nasosinusitis uses an antiseptic function, an anti-inflammatory function, etc. of the scutellaria root extracts, and directly acts on the focus. The nasal cavity preparation has obvious effect on treating rhinitis and nasosinusitis, and the present invention provides a novel medicine for rhinitis patients.
If withdrawal of ZIAC therapy is planned, it should be achieved gradually over a period of about 2 weeks. Patients should be carefully observed.

Patients with Renal or Hepatic Impairment: As noted in the WARNINGS section, caution must be used in dosing/titrating patients with hepatic impairment or renal dysfunction. Since there is no indication that hydrochlorothiazide is dialyzable, and limited data suggest that bisoprolol is not dialyzable, drug replacement is not necessary in patients undergoing dialysis.

Geriatric Patients: Dosage adjustment on the basis of age is not usually necessary, unless there is also significant renal or hepatic dysfunction (see above and WARNINGS section).

Pediatric Patients: There is no pediatric experience with ZIAC.